Global Cancer Biologics Market 2022-2026

Global Cancer Biologics Market 2022-2026

  • March 2022 •
  • 120 pages •
  • Report ID: 5773797 •
  • Format: PDF
Global Cancer Biologics Market 2022-2026
The analyst has been monitoring the cancer biologics market and it is poised to grow by $ 34.97 bn during 2022-2026 progressing at a CAGR of 8.91% during the forecast period. Our report on the cancer biologics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by rising global incidence of cancer, robust pipeline and new drug approvals, and significant therapeutic benefits of cancer biologics.
The cancer biologics market analysis includes the product segment and geographic landscape.

The cancer biologics market is segmented as below:
By Product
• Monoclonal antibodies
• Vaccines
• Cell and gene therapy
• Others

By Geographical Landscape
• North America
• Europe
• Asia
• Rest of World (ROW)

This study identifies the rise in strategic collaborations as one of the prime reasons driving the cancer biologics market growth during the next few years. Also, increase in R&D of innovative biologics and increased use of predictive biomarkers will lead to sizable demand in the market.

The analyst presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on cancer biologics market covers the following areas:
• Cancer biologics market sizing
• Cancer biologics market forecast
• Cancer biologics market industry analysis

This robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading cancer biologics market vendors that include Amgen Inc., AstraZeneca Plc, Bayer AG, Biocon Ltd., Biogen Inc., Bristol Myers Squibb Co., Celltrion Co. Ltd., Cipla Ltd., Dr. Reddys Laboratories Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Jazz Pharmaceuticals Plc, Johnson and Johnson, Lupin Ltd., Merck and Co. Inc., Novartis AG, Ono Pharmaceutical Co. Ltd., and Mylan NV. Also, the cancer biologics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The analyst presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio’s market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.